Lv62
2920 积分 2022-02-11 加入
"Is sotagliflozin a 'wonder drug'? A review of its impact on cardiovascular, diabetic, renal, neuroprotective, and hepatic outcomes"
4天前
已完结
Ferroptosis: a new target for hepatic ischemia-reperfusion injury?
2个月前
已完结
Dihydromyricetin Ameliorates Nonalcoholic Fatty Liver Disease by Improving Mitochondrial Respiratory Capacity and Redox Homeostasis Through Modulation of SIRT3 Signaling
3个月前
已完结
Electrolytes and acid–base: common fluid and electrolyte disorders
6个月前
已完结
Electrolyte Disorders: Causes, Diagnosis, and Initial Care—Part 3
6个月前
已完结
Electrolyte Disturbances and Repletion in Orthopaedic and Spine Surgery Patients
6个月前
已完结
International Consensus Criteria for Pediatric Sepsis and Septic Shock
6个月前
已完结
SGLT2 inhibitor dapagliflozin protects the kidney in a murine model of Balkan nephropathy
7个月前
已完结
Liver ischemia-reperfusion injury: From trigger loading to shot firing
9个月前
已完结
Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2
10个月前
已完结
皖公网安备34019202002308
